Foundayo was linked to body weight reductions of up to 13% in adults aged 65 and older living with obesity or overweight, according to a new analysis of the ATTAIN-1 and ATTAIN-2 trials.

Eli Lilly has recently shared a new analysis from the Phase 3 ATTAIN-1 and ATTAIN-2 trials demonstrating that Foundayo delivered clinically meaningful body weight reductions in adults aged 65 and older with obesity or overweight, with or without type 2 diabetes. Foundayo is the only approved GLP-1 tablet that can be taken at any time of day without food or water restrictions.

Key results: weight loss in adults aged 65 and older

In both trials, Foundayo at every dose tested delivered statistically significant body weight reductions compared with placebo at 72 weeks in adults aged 65 and older, using the efficacy estimand (all p<0.001).

Expert perspective: what the results could mean for patients

“Weight management in older adults requires careful consideration of both benefit and risk. These data are reassuring on both fronts — up to 13% weight loss was observed in patients 65 and older taking Foundayo, with a safety profile similar to what was observed in the broader trial populations,” said Rachel Batterham, M.D., senior vice president of medical innovation and external engagement, Lilly Cardiometabolic Health. “The fact that these results were achieved with a once-daily pill that patients can take at any time, without planning around meals or dealing with injections, matters in this age group.”

Key results: safety profile across age groups

Orforglipron’s safety profile was broadly consistent across age groups and in line with the overall ATTAIN-1 and ATTAIN-2 trial populations. Gastrointestinal adverse events sometimes severe, and including nausea, constipation, diarrhea, and vomiting were the most commonly reported events, in keeping with the GLP-1 receptor agonist class.

Pooled serious adverse events were reported by 5.6%, 6.2%, and 5.4% of participants under 65, and by 9.9%, 13.0%, and 11.6% of participants aged 65 and older, in the Foundayo 5.5 mg, 9 mg, and 17.2 mg groups, respectively, compared with 5.4% and 11.4% in the placebo group.

---

---

Related Topics and Keywords

ATTAIN-1, Foundayo, orforglipron